Recruiting at 102 sites Phase 2 Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer study: Rina-S

Official title Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT07288177

What this study is testing

What is Rina-S?

Rina-S is an investigational medicine being studied as a potential treatment for non-small cell lung cancer.

Also referred to as Rinatabart Sesutecan, PRO1184, GEN1184.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The study aims to see how well Rina‑S works against lung cancer and to check its safety.
Who it's for
It is looking for adults who have non‑small cell lung cancer.
What's involved
All participants will receive Rina‑S alone. They will visit the clinic 1 to 5 times each 3‑week cycle for blood tests, heart monitoring, and imaging to track safety and effectiveness.
Time commitment
The study lasts about 12 months on average, with regular clinic visits every 3 weeks for up to 5 visits per cycle.
  • Phase 2: a mid-size study of how well it works
  • You might receive a placebo (an inactive treatment) instead of the study drug.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older

You may be able to join if

  • Participant has histologically or cytologically confirmed metastatic or locally advanced NSCLC of adenocarcinoma histology, not amenable to curative...
  • Participant must have radiological disease progression while on or after receiving the most recent regimen.
  • Participants either may have actionable genetic alterations (AGAs) or no AGAs.
  • Participant has measurable disease according to RECIST v1.1.
  • Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1 within 7 days of Cycle 1 Day 1. Key

You likely can't join if

  • Participant has NSCLC with histology other than adenocarcinoma
  • Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of...
  • Participants with newly identified or known unstable (eg, progressing brain metastases) or symptomatic central nervous system (CNS) metastases or...

The study team makes the final eligibility decision.

Where it is enrolling

  • Fountain Valley, California, United States
  • Irvine, California, United States
  • San Diego, California, United States
  • Santa Rosa, California, United States
  • Washington D.C., District of Columbia, United States
  • Miami, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Billings, Montana, United States
  • Lincoln, Nebraska, United States
  • East Brunswick, New Jersey, United States
  • Albany, New York, United States
  • The Bronx, New York, United States
  • Chapel Hill, North Carolina, United States
  • Eugene, Oregon, United States
  • Portland, Oregon, United States
  • West Haven-Sylvan, Oregon, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Fairfax, Virginia, United States

+ 69 more site(s).

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Fountain Valley, California, United States; Irvine, California, United States; San Diego, California, United States; Santa Rosa, California, United States; Washington D.C., District of Columbia, United States; Miami, Florida, United States and 83 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.